

In an article¹ titled “A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia” by Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Ryota Shiibashi, Koji Izutsu, the authors would like to correct the description under section 3.3 in the Results section.

The sentence “These patients continued the study drug administration without interruption but were administered a reduced dose of tirabrutinib.” should read as “Both patients with epistaxis continued the study drug administration without interruption whereas the patient with mouth hemorrhage interrupted and resumed the tirabrutinib administration.”

The authors apologize for the error.

REFERENCE

1. Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. *Cancer Sci.* 2020;111:3327-3337.